Shuchi Nahar's Weekend Blog!

Neogen Chemicals - Q1FY23 Result Overview Neogen Chemicals Limited (Neogen) reported robust financial performance during the quarter ended 30th June, 2022. The Company delivered revenues of Rs. 147.9 crore in Q1 FY23, depicting a growth of 75%. The strong topline performance was driven by incremental benefits accruing from the expanded capacity. This was supported by continued positive demand across key products. Profit after tax (PAT) stood at Rs. 11.1 crore during the quarter as compared to Rs. 7.4 crore in Q1 FY22. Strong double-digit growth in PAT was aided by good operating performance. During the period under review, the Company witnessed significant increase in the prices of Lithium raw materials which Company was able to pass on to the customers, resultantly protecting the absolute EBITDA. The EBITDA percentage margin decline is optical as it considers higher revenues and higher RM costs with preserved absolute earnings. Neogen Chemical Investor Presentation Developments  An es

Chambal Fertilizers - Company overview &  Urea industry synopsis in India Twitter Handle: @shuchi_nahar Company Overview   Incorporated in 1985 and based in Kota, Rajasthan, Chambal has the largest installed urea capacity of 3.00 million tonnes in the private sector in India. Chambal is the largest private player in the urea industry in India in terms of production capacity. Its share in the total domestic urea production has increased to 13.4%, driven by the ramp-up of its Gadepan-III plant. The company has maintained its share in the non-urea fertilizers segment. The company has sold 0.93 million tonnes of DAP/muriate of potash/nitrogen phosphorus potassium during the first 9 months of fiscal 2022, down from 1.60 million tonnes in the corresponding period of the previous fiscal because of the global shortage of the fertilizers amidst the Russia-Ukraine war. Its significant market share in north India is supported by its strong Uttam Vir brand and robust distribution network. Th

Healthcare Global Enterprise Ltd. -  India's Leading Oncology Focused Network Background Established in 1989, Healthcare Global Enterprises Limited (HCG), is present primarily in the oncology field with the largest cancer care network (with 22 cancer care centers as of December 2021) and three multi-specialty hospitals. It is promoted by Dr. B.S. Ajai Kumar, practicing radiation and medical oncologist with over 30 years of experience. Originally established with a single cancer care center, the Bangalore Institute of Oncology (BIO), at Bangalore by Dr. B.S. Ajai Kumar and four other oncologists, the company has rapidly expanded its presence to Ahmedabad, Chennai, Nasik, Ranchi, Rajkot, Cuttack, Hubli, Mumbai, Nagpur, Vizag, and Vijayawada, among others. The company is now present across the oncology value chain, offering services from prevention, screening, diagnosis, and treatment to rehabilitation, supportive care, and palliative care. Pursuant to the Investment Agreement enter

  India's Biotechnology Industry Size, Opportunities, and Investments  Twitter Handle: @shuchi_nahar Link to my previous biotechnology blog: https://myweekendspot.blogspot.com/2021/05/biotechnology-way-towards-bio-based.html India’s Biotechnology Industry The Indian biotechnology industry amounted to US$ 63 billion in 2019 and is forecast to reach US$ 150 billion by 2025, with a CAGR of 16.4%. By 2025, the contribution of the Indian biotechnology industry in the global biotechnology market is expected to grow to 19% from 3% in 2017. Bio-services, which accounted for 15% of the biotechnology industry in India, is becoming a leading destination for clinical trials, contract research, and manufacturing activities in the country. • In FY20, the sector grew 15% year on year • By FY24, the contribution of the Indian biotechnology industry in the global biotechnology market is expected to grow to 19% from 3% in FY18 • India has over 4237+ biotech startups and is expected to have over

Laurus Labs - Result Update Q4FY21 & Full Year FY21 Twitter Handle: @shuchi_nahar Laurus Labs Limited on 30th April 2021 announced its Q4FY21 and full-year results.  Laurus Lab performed extremely well consecutive in the 4th Quarter of FY21. The company did a robust growth in all three segments. Having a healthy order book for FY 22. Consolidated revenue for the quarter increased by 70% driven by growth in all the divisions. The company has been able to sustain its EBITDA margins, and profitability has also improved to Rs. 297 Crs. for the quarter. Generic API division showcased a robust growth of 61% YoY. Anti Viral segment recorded a robust growth of 70% YoY. Revenue Showcased a healthy growth of 102% YoY. The growth was led by higher LMIC Market volumes and increased volumes from North America and EU Commenced marketing of in-licensed products in the USA to leverage front-end capabilities. Custom Synthesis division recorded a strong growth of 35% YoY. Capacity Expansion – To